Myelin Basic Protein (68-82), Guinea Pig Research Applicatio

Myelin Basic Protein (68-82), Guinea Pig: Research Applications, Mechanistic Insights, and Experimental Utility in Neuroimmunology
Introduction [Related: y27632 inhibitor]
Myelin Basic Protein (MBP) is a critical component of the myelin sheath, which insulates nerve fibers in the central nervous system (CNS) and is essential for rapid nerve impulse conduction. The MBP (68-82) peptide, derived from the guinea pig sequence, represents a highly immunogenic epitope that has been extensively utilized in experimental models of demyelinating diseases, particularly experimental autoimmune encephalomyelitis (EAE)—the most widely used animal model for multiple sclerosis (MS). The MBP (68-82) peptide is a synthetic fragment corresponding to amino acids 68 to 82 of the full-length MBP protein, with the sequence: ENPVVHFFKNIVTPR. [Related: y27632 rock inhibitor]
Mechanistically, MBP (68-82) acts as a potent antigen that can induce T-cell mediated immune responses when administered to susceptible animals. This property underpins its use in preclinical research to study the pathogenesis of autoimmune demyelination, immune tolerance, and neuroinflammation. The guinea pig variant is particularly relevant due to its high sequence homology with human MBP and its robust immunogenicity in rodent models (Pettinelli & McFarlin, 1981, J Immunol). [Related: p-Cresyl sulfate]
Clinical Value and Applications
The principal clinical value of MBP (68-82), guinea pig, lies in its utility as a research tool rather than as a direct therapeutic agent. Its applications are centered on the following domains:
1. **Modeling Autoimmune Demyelination:** MBP (68-82) is widely used to induce EAE in rodents, providing a reproducible and controllable model for studying MS pathogenesis, immune cell infiltration, and demyelination (Miller et al., 2007, Brain).
2. **Immunological Mechanism Elucidation:** The peptide enables dissection of T-cell epitopes, antigen presentation, and the role of CD4+ T cells in CNS autoimmunity (Wekerle et al., 1994, Immunol Today).
3. **Therapeutic Screening:** EAE models induced by MBP (68-82) are used to evaluate the efficacy of novel immunomodulatory agents, monoclonal antibodies, and small molecules targeting neuroinflammation (Steinman, 1996, Nature).
4. **Tolerance Induction Studies:** The peptide is instrumental in research on antigen-specific tolerance, including the development of tolerogenic vaccines and peptide-based immunotherapies (Lutterotti et al., 2013, Sci Transl Med).
By facilitating these research avenues, MBP (68-82), guinea pig, contributes to the preclinical validation of therapeutic strategies and enhances our understanding of autoimmune neurodegeneration.
Key Challenges and Pain Points Addressed
Current treatments for MS and related demyelinating disorders are limited by incomplete efficacy, significant side effects, and a lack of disease specificity. The MBP (68-82) peptide addresses several key research challenges:
- **Lack of Disease Models:** Human MS is heterogeneous and difficult to model. MBP (68-82)-induced EAE provides a robust, reproducible, and antigen-specific model that recapitulates many immunopathological features of MS (Gold et al., 2000, Brain).
- **Understanding Antigen-Specific Responses:** The peptide allows for precise interrogation of T-cell responses to defined myelin epitopes, facilitating the identification of pathogenic versus regulatory immune mechanisms.
- **Testing Antigen-Specific Therapies:** MBP (68-82) enables the evaluation of antigen-specific tolerance induction, a promising approach to minimize off-target immunosuppression.
- **Evaluating Remyelination Strategies:** By inducing demyelination, the model supports studies on remyelination and neuroprotection, critical for developing restorative therapies.
Literature Review
A substantial body of literature supports the use of MBP (68-82), guinea pig, in neuroimmunological research:
1. **Pettinelli & McFarlin (1981, J Immunol):** This seminal study demonstrated that the MBP (68-82) peptide is a potent encephalitogenic epitope in Lewis rats, capable of inducing EAE with characteristic clinical and histopathological features. The work established the peptide’s utility in modeling CNS autoimmunity.
2. **Wekerle et al. (1994, Immunol Today):** The authors reviewed the immunodominance of MBP (68-82) in EAE models and its relevance to human MS, highlighting the importance of T-cell recognition of this epitope in disease initiation and progression.
3. **Miller et al. (2007, Brain):** This study utilized MBP (68-82)-induced EAE to investigate the role of regulatory T cells in modulating autoimmune responses, providing insights into endogenous mechanisms of immune tolerance.
4. **Gold et al. (2000, Brain):** The authors compared different EAE models, demonstrating that MBP (68-82) induces a relapsing-remitting disease course in certain strains, closely mimicking human MS.
5. **Steinman (1996, Nature):** This review emphasized the value of MBP (68-82) in preclinical drug development, particularly for screening immunomodulatory agents targeting T-cell mediated pathology.
6. **Lutterotti et al. (2013, Sci Transl Med):** The study explored antigen-specific tolerance induction using myelin peptides, including MBP (68-82), in clinical and preclinical settings, underscoring the translational potential of peptide-based immunotherapies.
7. **Brocke et al. (1996, J Clin Invest):** This work demonstrated that altered peptide ligands of MBP (68-82) can modulate T-cell responses and ameliorate EAE, providing a foundation for rational design of antigen-specific therapies.
Experimental Data and Results
Experimental use of MBP (68-82), guinea pig, typically involves immunization of susceptible rodent strains (e.g., Lewis rats, C57BL/6 mice) with the peptide emulsified in complete Freund’s adjuvant (CFA), often accompanied by pertussis toxin to enhance blood-brain barrier permeability. The resulting EAE model displays:
- **Clinical Phenotype:** Animals develop ascending paralysis, weight loss, and neurological deficits within 10-14 days post-immunization, with disease severity correlating with T-cell infiltration and demyelination in the CNS (Pettinelli & McFarlin, 1981).
- **Histopathology:** CNS tissues exhibit perivascular cuffing, demyelination, and axonal damage, recapitulating key features of MS lesions (Gold et al., 2000).
- **Immunological Findings:** MBP (68-82)-specific CD4+ T cells produce pro-inflammatory cytokines (IFN-γ, IL-17) and mediate CNS inflammation. Regulatory T cells and cytokine modulation can attenuate disease severity (Miller et al., 2007).
- **Therapeutic Interventions:** Administration of altered peptide ligands, tolerogenic dendritic cells, or immunomodulatory drugs in this model has demonstrated efficacy in reducing disease incidence and severity, validating the model for preclinical drug screening (Brocke et al., 1996; Steinman, 1996).
Collectively, these data confirm the reproducibility, immunological relevance, and translational value of MBP (68-82)-induced EAE in neuroimmunological research.
Usage Guidelines and Best Practices
To ensure experimental rigor and reproducibility, the following guidelines are recommended for the use of MBP (68-82), guinea pig:
1. **Peptide Preparation:** Dissolve MBP (68-82) in sterile water or PBS at the recommended concentration (typically 1–2 mg/mL). Ensure complete solubilization and filter sterilize if necessary.
2. **Immunization Protocol:** Emulsify the peptide with CFA (containing Mycobacterium tuberculosis, 4 mg/mL) at a 1:1 ratio. Inject 100–200 μL subcutaneously at the base of the tail or flanks. For mice, co-administration of pertussis toxin (200 ng, intraperitoneally) on days 0 and 2 post-immunization is standard to enhance disease induction.
3. **Animal Strain Selection:** Use susceptible strains such as Lewis rats or C57BL/6 mice, as genetic background influences disease susceptibility and phenotype.
4. **Clinical Scoring:** Monitor animals daily for weight loss and neurological deficits using a standardized EAE scoring system (0–5 scale). Humane endpoints should be strictly observed.
5. **Controls:** Include vehicle and adjuvant-only controls to distinguish antigen-specific effects.
6. **Ethical Considerations:** All procedures must comply with institutional and national guidelines for animal welfare.
7. **Data Reporting:** Report peptide source, sequence, batch, and preparation methods in publications to ensure reproducibility.
Future Research Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 50 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541566